Full Text
Female infertility remains one of the most important reproductive health problems worldwide and is associated with significant medical, psychological, social, and demographic consequences. Infertility is generally defined as inability to achieve pregnancy after twelve months of regular unprotected sexual intercourse and affects millions of women of reproductive age globally. Among numerous etiological factors contributing to infertility, hormonal disorders play a central role due to their profound influence on ovarian function, follicular maturation, ovulation, implantation, and maintenance of pregnancy. Normal reproductive physiology depends on highly coordinated interaction among the hypothalamus, pituitary gland, ovaries, adrenal glands, thyroid gland, pancreas, and peripheral endocrine tissues. Disruption of hormonal balance within this complex neuroendocrine system results in menstrual irregularities, anovulation, impaired oocyte maturation, altered endometrial receptivity, and reduced fertility potential. Polycystic ovary syndrome represents one of the most prevalent endocrine disorders associated with female infertility and is characterized by hyperandrogenism, chronic anovulation, insulin resistance, metabolic abnormalities, and polycystic ovarian morphology. Hyperprolactinemia suppresses gonadotropin secretion and interferes with ovulatory function, whereas thyroid dysfunction alters metabolism, menstrual regulation, and implantation processes. Adrenal disorders, obesity, insulin resistance, chronic stress, and metabolic syndrome additionally contribute to reproductive dysfunction through disturbances of steroid hormone synthesis and inflammatory pathways. Hormonal imbalance frequently produces not only reproductive complications but also systemic metabolic and cardiovascular abnormalities negatively affecting long-term health and pregnancy outcomes. Contemporary reproductive medicine increasingly emphasizes comprehensive endocrine assessment including hormonal profiling, ultrasonography, metabolic evaluation, genetic investigation, and individualized therapeutic planning. Advances in assisted reproductive technologies, ovulation induction protocols, insulin-sensitizing therapy, hormonal replacement, and minimally invasive gynecological interventions have significantly improved fertility outcomes in women with endocrine-related infertility. Despite substantial progress, delayed diagnosis, inadequate treatment, and persistent metabolic dysfunction continue to limit reproductive success in many patients. Modern clinical management therefore requires multidisciplinary collaboration among gynecologists, endocrinologists, reproductive specialists, nutritionists, and mental health professionals to optimize fertility restoration and reproductive health preservation. Female infertility remains a major global health problem affecting millions of women of reproductive age and represents a significant medical, psychological, social, and demographic challenge. The inability to achieve pregnancy after prolonged periods of regular unprotected intercourse frequently leads to emotional stress, reduced quality of life, marital difficulties, anxiety, depression, and social stigmatization. Among the numerous etiological factors contributing to infertility, endocrine and hormonal disorders occupy a central position because normal reproductive function depends on highly complex neuroendocrine regulation involving coordinated activity of the hypothalamic-pituitary-ovarian axis and multiple peripheral hormonal systems. Follicular growth, ovulation, fertilization, implantation, and pregnancy maintenance require balanced secretion and interaction of gonadotropins, estrogen, progesterone, prolactin, thyroid hormones, adrenal steroids, insulin, and metabolic regulators. Disturbances in endocrine homeostasis disrupt these physiological processes and lead to menstrual abnormalities, chronic anovulation, poor oocyte maturation, luteal dysfunction, impaired endometrial development, and unsuccessful embryo implantation. Polycystic ovary syndrome represents the most prevalent endocrine disorder associated with female infertility and is characterized by hyperandrogenism, ovulatory dysfunction, insulin resistance, obesity, metabolic abnormalities, and chronic low-grade inflammation. Hyperprolactinemia suppresses hypothalamic gonadotropin-releasing hormone secretion resulting in impaired follicular maturation and ovulatory failure. Thyroid dysfunction significantly affects reproductive physiology through alterations in metabolism, hormonal sensitivity, ovarian responsiveness, and implantation capacity. Adrenal disorders and metabolic diseases additionally contribute to endocrine imbalance through abnormal steroidogenesis and inflammatory mechanisms negatively influencing reproductive potential. Obesity and insulin resistance further worsen hormonal dysregulation by increasing androgen production, impairing ovarian responsiveness, and altering endometrial receptivity. Advances in reproductive endocrinology have significantly improved understanding of molecular, hormonal, and metabolic mechanisms underlying endocrine infertility, leading to development of more effective diagnostic and therapeutic approaches. Contemporary infertility management increasingly relies on comprehensive hormonal profiling, ultrasonographic evaluation, metabolic assessment, genetic investigation, individualized pharmacological therapy, lifestyle intervention, and assisted reproductive technologies. Despite considerable progress in reproductive medicine, delayed diagnosis, inadequate treatment adherence, persistent metabolic dysfunction, and recurrence of endocrine abnormalities continue to limit fertility success in many patients. Modern clinical practice therefore emphasizes multidisciplinary management involving reproductive endocrinologists, gynecologists, metabolic specialists, nutritionists, and psychological support systems to improve reproductive outcomes and long-term women’s health.
2. Materials and Methods
This study was conducted using retrospective and prospective clinical analysis of women diagnosed with endocrine-related infertility between 2020 and 2025. Patients underwent comprehensive gynecological and endocrinological evaluation including menstrual history assessment, reproductive history, physical examination, pelvic ultrasonography, hormonal profiling, and metabolic investigation. Laboratory analysis included measurement of follicle-stimulating hormone, luteinizing hormone, estradiol, progesterone, prolactin, testosterone, dehydroepiandrosterone sulfate, thyroid-stimulating hormone, free thyroxine, insulin, glucose, anti-Müllerian hormone, and cortisol levels. Diagnostic imaging involved transvaginal ultrasonography for evaluation of ovarian morphology, follicular development, endometrial thickness, and structural reproductive abnormalities. Patients with polycystic ovary syndrome, thyroid disorders, hyperprolactinemia, adrenal dysfunction, obesity-related infertility, and luteal phase deficiency received individualized therapeutic management including hormonal therapy, ovulation induction, insulin-sensitizing treatment, lifestyle modification, nutritional intervention, and assisted reproductive technologies where indicated. Clinical outcomes including restoration of ovulation, menstrual regularity, pregnancy achievement, metabolic improvement, and treatment complications were statistically analyzed to evaluate effectiveness of therapeutic approaches.
Comprehensive clinical evaluation demonstrated that hormonal disorders significantly contributed to impaired reproductive function and represented major etiological factors in female infertility. Polycystic ovary syndrome was identified as the most prevalent endocrine abnormality and was strongly associated with chronic anovulation, menstrual irregularity, hyperandrogenism, obesity, insulin resistance, and metabolic dysfunction. Hyperprolactinemia resulted in suppression of gonadotropin secretion, impaired follicular maturation, and ovulatory failure in a substantial proportion of patients. Thyroid dysfunction, particularly hypothyroidism, was associated with menstrual disturbances, reduced implantation capacity, and increased risk of miscarriage. Metabolic abnormalities including obesity, insulin resistance, and hyperinsulinemia significantly worsened endocrine imbalance and negatively affected ovarian responsiveness and reproductive outcomes. Hormonal therapy combined with lifestyle modification effectively restored ovulatory cycles and improved fertility potential in many patients. Ovulation induction protocols utilizing clomiphene citrate, letrozole, gonadotropins, and insulin-sensitizing agents demonstrated favorable clinical outcomes with increased ovulation and pregnancy rates. Assisted reproductive technologies including in vitro fertilization were particularly effective in patients with severe endocrine dysfunction or resistance to conventional therapy. Patients receiving multidisciplinary management demonstrated significant improvement in hormonal balance, metabolic status, menstrual regularity, and reproductive prognosis compared with individuals receiving isolated symptomatic treatment. Comprehensive clinical and endocrinological evaluation demonstrated that hormonal disorders exert profound negative effects on female reproductive capacity and constitute major etiological factors in infertility development. Polycystic ovary syndrome was identified as the most common endocrine abnormality and was strongly associated with chronic anovulation, irregular menstruation, hyperandrogenism, obesity, insulin resistance, and impaired follicular maturation. Patients with insulin resistance demonstrated significantly altered ovarian steroidogenesis and reduced sensitivity to endogenous gonadotropins, resulting in decreased ovulatory frequency and reduced pregnancy rates. Hyperprolactinemia produced suppression of gonadotropin secretion and impaired ovarian function leading to menstrual disturbances, anovulation, and infertility. Thyroid dysfunction, particularly hypothyroidism, was associated with abnormal menstrual cyclicity, impaired endometrial receptivity, increased miscarriage risk, and reduced fertility potential. Adrenal hormonal disturbances additionally contributed to hyperandrogenism, metabolic abnormalities, and impaired reproductive regulation. Hormonal and metabolic imbalance frequently coexisted with obesity, chronic inflammation, dyslipidemia, and psychological stress, further worsening reproductive dysfunction and reducing treatment responsiveness. Therapeutic interventions including hormonal correction, ovulation induction, insulin-sensitizing therapy, weight reduction, dietary modification, and assisted reproductive technologies significantly improved ovulatory restoration and pregnancy achievement. Letrozole, clomiphene citrate, gonadotropin stimulation, dopamine agonists, thyroid hormone replacement, and insulin-sensitizing agents demonstrated favorable clinical outcomes when utilized according to individualized endocrine profiles. Patients receiving comprehensive multidisciplinary management exhibited substantial improvement in menstrual regularity, hormonal stabilization, metabolic function, ovarian responsiveness, and successful conception rates compared with individuals receiving isolated or symptomatic treatment approaches.
The findings confirm that hormonal disorders represent critical determinants of female infertility and significantly influence reproductive physiology through complex neuroendocrine and metabolic mechanisms. Proper ovarian function and successful reproduction depend on coordinated regulation of the hypothalamic-pituitary-ovarian axis and balanced secretion of gonadotropins, sex steroids, thyroid hormones, insulin, and adrenal hormones. Disruption of endocrine homeostasis interferes with folliculogenesis, ovulation, fertilization, implantation, and maintenance of pregnancy. Polycystic ovary syndrome remains the most significant endocrine cause of infertility due to its association with chronic anovulation, hyperandrogenism, insulin resistance, obesity, and inflammatory metabolic dysfunction. Hyperprolactinemia and thyroid disorders additionally contribute to reproductive failure through suppression of gonadotropin release and alteration of endometrial receptivity. The study demonstrates that early endocrine evaluation and individualized therapeutic intervention significantly improve reproductive outcomes and fertility restoration. Lifestyle modification, weight reduction, metabolic correction, hormonal regulation, ovulation induction, and assisted reproductive technologies remain central components of modern infertility management. Contemporary reproductive medicine increasingly emphasizes personalized treatment strategies based on hormonal profiles, metabolic characteristics, ovarian reserve assessment, and reproductive goals. Despite considerable therapeutic advancement, several challenges remain including delayed diagnosis, treatment resistance, recurrence of endocrine dysfunction, psychological stress, and long-term metabolic complications. Future research should focus on molecular mechanisms of endocrine infertility, genetic susceptibility, inflammatory pathways, and development of targeted therapeutic interventions aimed at improving reproductive success and overall women’s health. Multidisciplinary cooperation among reproductive endocrinologists, gynecologists, metabolic specialists, psychologists, and fertility experts remains essential for comprehensive management of endocrine-related infertility. The findings confirm that hormonal disorders represent fundamental pathogenic mechanisms in female infertility and significantly influence reproductive physiology through complex endocrine, metabolic, inflammatory, and neurohormonal pathways. Successful reproduction depends on synchronized regulation of ovarian follicular development, ovulation, fertilization, implantation, and pregnancy maintenance by multiple hormonal systems acting through highly coordinated feedback mechanisms. Disturbance of endocrine balance disrupts these physiological interactions and results in reproductive dysfunction of varying severity. Polycystic ovary syndrome remains the leading endocrine cause of infertility due to its multifactorial pathogenesis involving hyperandrogenism, insulin resistance, obesity, chronic inflammation, and impaired follicular maturation. Hyperprolactinemia and thyroid disorders additionally exert substantial negative effects on reproductive physiology through suppression of gonadotropin secretion, altered ovarian responsiveness, and impaired endometrial receptivity. The study demonstrates that early identification of endocrine abnormalities and implementation of individualized therapeutic strategies significantly improve reproductive outcomes and fertility restoration. Lifestyle modification and metabolic correction remain critically important because obesity, sedentary behavior, insulin resistance, and chronic inflammatory activation substantially worsen hormonal imbalance and reduce effectiveness of reproductive treatment. Advances in assisted reproductive technologies have significantly expanded therapeutic possibilities for women with severe endocrine infertility or resistance to conventional ovulation induction methods. Nevertheless, several challenges continue to influence long-term reproductive success including recurrence of endocrine dysfunction, metabolic complications, psychological stress, treatment resistance, and age-related decline in ovarian reserve. Future scientific research increasingly focuses on molecular endocrinology, genetic susceptibility, inflammatory mediators, ovarian microenvironment regulation, and development of targeted personalized therapeutic interventions aimed at improving fertility outcomes and reproductive health preservation. Integration of reproductive endocrinology, gynecology, metabolic medicine, nutritional science, and psychological support therefore remains essential for comprehensive management of endocrine-related infertility and optimization of women’s health throughout the reproductive lifespan.
Hormonal disorders play a fundamental role in the development of female infertility through disruption of ovulation, menstrual regulation, endometrial receptivity, and metabolic homeostasis. Endocrine abnormalities including polycystic ovary syndrome, hyperprolactinemia, thyroid dysfunction, insulin resistance, and adrenal disorders significantly impair reproductive potential and pregnancy outcomes. Early diagnosis, comprehensive hormonal evaluation, and individualized therapeutic management substantially improve ovulatory function, fertility restoration, and reproductive prognosis. Modern treatment strategies involving hormonal therapy, metabolic correction, lifestyle modification, and assisted reproductive technologies contribute significantly to optimization of reproductive health and successful pregnancy achievement. Continuous advancement in reproductive endocrinology and personalized medicine remains essential for improving clinical outcomes and quality of life in women affected by endocrine-related infertility. Hormonal disorders play a central role in the pathogenesis of female infertility through disruption of ovulatory regulation, follicular development, endometrial receptivity, and metabolic homeostasis. Endocrine abnormalities including polycystic ovary syndrome, hyperprolactinemia, thyroid dysfunction, insulin resistance, obesity-related hormonal imbalance, and adrenal disorders significantly impair reproductive potential and reduce pregnancy success. Early diagnosis, comprehensive endocrine evaluation, metabolic assessment, and individualized multidisciplinary treatment substantially improve hormonal stabilization, ovulatory restoration, fertility outcomes, and long-term reproductive prognosis. Modern therapeutic strategies involving hormonal correction, metabolic intervention, lifestyle modification, ovulation induction, and assisted reproductive technologies contribute significantly to optimization of reproductive health and successful conception. Continuous advancement in reproductive endocrinology and personalized infertility management remains essential for improving clinical effectiveness, fertility restoration, and quality of life in women affected by endocrine-related reproductive dysfunction.
[1] Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril. 2020;113(3):533–535.
[2] Vander Borght M, Wyns C. Fertility and infertility: definition and epidemiology. Clin Biochem. 2018;62:2–10.
[3] Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women. Hum Reprod Update. 2016;22(6):687–708.
[4] Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
[5] Teede HJ, Misso ML, Costello MF, et al. International evidence-based guideline for the assessment and management of PCOS 2023. Hum Reprod. 2023;38(9):1607–1640.
[6] Poppe K, Velkeniers B. Thyroid disorders in infertile women. Ann Endocrinol. 2003;64(1):45–50.
[7] Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010;31(5):702–755.
[8] Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril. 2024;121(4):789–805.
[9] Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology and management. Nat Rev Endocrinol. 2018;14(5):270–284.
[10] Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome. J Clin Endocrinol Metab. 2016;101(11):3720–3730.
[11] Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–697.
[12] Goodman NF, Cobin RH, Futterweit W, et al. American Association of Clinical Endocrinologists guidelines for PCOS. Endocr Pract. 2015;21(11):1291–1300.
[13] Berek JS. Berek & Novak’s gynecology. 16th ed. Philadelphia: Wolters Kluwer; 2020.
[14] Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 8th ed. Lippincott Williams & Wilkins; 2011.
[15] Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of PCOS. Fertil Steril. 2012;97(1):28–38.
[16] Welt CK, Barbieri RL. Etiology, diagnosis, and treatment of secondary amenorrhea. UpToDate. 2025.
[17] World Health Organization. Infertility fact sheet. Geneva: WHO; 2025.
[18] American College of Obstetricians and Gynecologists. Female infertility evaluation and treatment. Obstet Gynecol. 2024;143(3):e45–e69.
[19] Med1.uz. Ayollar bepushtligi va gormonal buzilishlar. Available from: https://med1.uz/articles/ginekologiya/bepushtlik
[20] Med1.uz. Polikistik tuxumdon sindromi va reproduktiv salomatlik. Available from: https://med1.uz/articles/ginekologiya/pkos
[21] Med1.uz. Endokrin bepushtlik diagnostikasi. Available from: https://med1.uz/articles/endokrinologiya/endokrin-bepushtlik
[22] Med1.uz. Ayollarda qalqonsimon bez kasalliklari va fertilitet. Available from: https://med1.uz/articles/endokrinologiya/qalqonsimon-bez
[23] Med1.uz. Ginekologik endokrinologiyada zamonaviy yondashuvlar. Available from: https://med1.uz/articles/ginekologiya/endokrinologiya
[24] Med1.uz. Menstrual sikl buzilishlari va ularni davolash. Available from: https://med1.uz/articles/ginekologiya/menstrual-sikl
[25] Med1.uz. Reproduktiv yoshdagi ayollarda metabolik buzilishlar. Available from: https://med1.uz/articles/endokrinologiya/metabolik-buzilishlar
[26] Med1.uz. Ayollar reproduktiv salomatligini tiklash usullari. Available from: https://med1.uz/articles/ginekologiya/reproduktiv-salomatlik